234 related articles for article (PubMed ID: 27485079)
1. Current status of engineered T-cell therapy for synovial sarcoma.
Dallos M; Tap WD; D'Angelo SP
Immunotherapy; 2016 Sep; 8(9):1073-80. PubMed ID: 27485079
[TBL] [Abstract][Full Text] [Related]
2. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
[TBL] [Abstract][Full Text] [Related]
3. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
[TBL] [Abstract][Full Text] [Related]
4. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor.
Joseph J; Nathenson MJ; Trinh VA; Malik K; Nowell E; Carter K; Weathers SP; Demetri GD; Araujo D; Conley AP
J Immunother Cancer; 2019 Nov; 7(1):296. PubMed ID: 31703609
[TBL] [Abstract][Full Text] [Related]
5. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
Robbins PF; Morgan RA; Feldman SA; Yang JC; Sherry RM; Dudley ME; Wunderlich JR; Nahvi AV; Helman LJ; Mackall CL; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Levy CL; Li YF; El-Gamil M; Schwarz SL; Laurencot C; Rosenberg SA
J Clin Oncol; 2011 Mar; 29(7):917-24. PubMed ID: 21282551
[TBL] [Abstract][Full Text] [Related]
6. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
Lai JP; Robbins PF; Raffeld M; Aung PP; Tsokos M; Rosenberg SA; Miettinen MM; Lee CC
Mod Pathol; 2012 Jun; 25(6):854-8. PubMed ID: 22388761
[TBL] [Abstract][Full Text] [Related]
7. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
[TBL] [Abstract][Full Text] [Related]
8. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1
D'Angelo SP; Melchiori L; Merchant MS; Bernstein D; Glod J; Kaplan R; Grupp S; Tap WD; Chagin K; Binder GK; Basu S; Lowther DE; Wang R; Bath N; Tipping A; Betts G; Ramachandran I; Navenot JM; Zhang H; Wells DK; Van Winkle E; Kari G; Trivedi T; Holdich T; Pandite L; Amado R; Mackall CL
Cancer Discov; 2018 Aug; 8(8):944-957. PubMed ID: 29891538
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities.
Kuramitsu S; Yamamichi A; Ohka F; Motomura K; Hara M; Natsume A
Immunotherapy; 2016 Dec; 8(12):1393-1404. PubMed ID: 28000534
[TBL] [Abstract][Full Text] [Related]
10. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy.
Kohli K; Yao L; Nowicki TS; Zhang S; Black RG; Schroeder BA; Farrar EA; Cao J; Sloan H; Stief D; Cranmer LD; Wagner MJ; Hawkins DS; Pillarisetty VG; Ribas A; Campbell J; Pierce RH; Kim EY; Jones RL; Riddell SR; Yee C; Pollack SM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963013
[TBL] [Abstract][Full Text] [Related]
11. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.
Kawai A; Woodruff J; Healey JH; Brennan MF; Antonescu CR; Ladanyi M
N Engl J Med; 1998 Jan; 338(3):153-60. PubMed ID: 9428816
[TBL] [Abstract][Full Text] [Related]
12. First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.
Pollack SM; Lu H; Gnjatic S; Somaiah N; O'Malley RB; Jones RL; Hsu FJ; Ter Meulen J
J Immunother; 2017 Oct; 40(8):302-306. PubMed ID: 28891906
[TBL] [Abstract][Full Text] [Related]
13. Unleash the power of the mighty T cells-basis of adoptive cellular therapy.
Sukari A; Abdallah N; Nagasaka M
Crit Rev Oncol Hematol; 2019 Apr; 136():1-12. PubMed ID: 30878123
[TBL] [Abstract][Full Text] [Related]
14. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
Ikeda H
Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
[TBL] [Abstract][Full Text] [Related]
15. Co-existence of SYT-SSX1 and SYT-SSX2 fusions in synovial sarcomas.
Yang K; Lui WO; Xie Y; Zhang A; Skytting B; Mandahl N; Larsson C; Larsson O
Oncogene; 2002 Jun; 21(26):4181-90. PubMed ID: 12037676
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
17. Cryptic chromosome rearrangement resulting in SYT-SSX2 fusion gene in a monophasic synovial sarcoma.
Torres L; Lisboa S; Cerveira N; Lopes JM; Lopes C; Teixeira MR
Cancer Genet Cytogenet; 2008 Nov; 187(1):45-9. PubMed ID: 18992642
[TBL] [Abstract][Full Text] [Related]
18. Treating cancer with genetically engineered T cells.
Park TS; Rosenberg SA; Morgan RA
Trends Biotechnol; 2011 Nov; 29(11):550-7. PubMed ID: 21663987
[TBL] [Abstract][Full Text] [Related]
19. SYT-SSX fusion genes in synovial sarcoma of the thorax.
Yano M; Toyooka S; Tsukuda K; Dote H; Morimoto Y; Ohata N; Ichimura K; Aoe M; Date H; Shimizu N
Lung Cancer; 2004 Jun; 44(3):391-7. PubMed ID: 15140553
[TBL] [Abstract][Full Text] [Related]
20. Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.
Moon EK; Ranganathan R; Eruslanov E; Kim S; Newick K; O'Brien S; Lo A; Liu X; Zhao Y; Albelda SM
Clin Cancer Res; 2016 Jan; 22(2):436-47. PubMed ID: 26324743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
